NasdaqGS - Delayed Quote USD
Neumora Therapeutics, Inc. (NMRA)
At close: November 6 at 4:00 PM EST
After hours: 7:12 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-198,328.00
-163,278.00
-114,896.00
-75,420.00
-26,760.00
Investing Cash Flow
-91,254.00
64,387.00
-168,013.00
-817.00
-11,237.00
Financing Cash Flow
236,042.00
231,936.00
115,743.00
293,507.00
230,099.00
End Cash Position
151,891.00
375,251.00
242,206.00
409,372.00
192,102.00
Capital Expenditure
--
-117.00
-511.00
-817.00
-1,300.00
Issuance of Capital Stock
--
233,375.00
112,216.00
292,139.00
174,196.00
Issuance of Debt
--
--
--
--
55,905.00
Repurchase of Capital Stock
--
-491.00
--
--
-2.00
Free Cash Flow
-198,409.00
-163,395.00
-115,407.00
-76,237.00
-28,060.00
12/31/2020 - 9/14/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LXEO Lexeo Therapeutics, Inc.
8.20
+2.12%
ANAB AnaptysBio, Inc.
22.21
+11.72%
PRAX Praxis Precision Medicines, Inc.
71.87
-1.18%
ACLX Arcellx, Inc.
92.98
+6.73%
TYRA Tyra Biosciences, Inc.
17.12
+2.15%
CNTA Centessa Pharmaceuticals plc
15.99
-0.06%
TNGX Tango Therapeutics, Inc.
3.2400
-37.45%
KYMR Kymera Therapeutics, Inc.
49.48
+3.75%
ATXS Astria Therapeutics, Inc.
11.87
+3.13%
NRIX Nurix Therapeutics, Inc.
27.00
+6.17%